Loss of Pediatric Kidney Grafts During the “High–Risk Age Window”: Insights From Pediatric Liver and Simultaneous Liver–Kidney Recipients

K. J. Van Arendonk¹, E. A. King¹, B. J. Orandi¹, N. T. James¹, J. M. Smith², P. M. Colombani¹, J. C. Magee³ and D. L. Segev¹,⁴,*

¹Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD
²Department of Pediatrics, University of Washington School of Medicine, Seattle, WA
³Department of Surgery, University of Michigan Medical School, Ann Arbor, MI
⁴Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, MD
*Corresponding author: Dorry Segev, dorry@jhmi.edu

Pediatric kidney transplant recipients experience a high–risk age window of increased graft loss during late adolescence and early adulthood that has been attributed primarily to sociobehavioral mechanisms such as nonadherence. An examination of how this age window affects recipients of other organs may inform the extent to which sociobehavioral mechanisms are to blame or whether kidney-specific biologic mechanisms may also exist. Graft loss risk across current recipient age was compared between pediatric kidney (n = 17,446), liver (n = 12,161) and simultaneous liver–kidney (n = 224) transplants using piecewise-constant hazard rate models. Kidney graft loss during late adolescence and early adulthood (ages 17–24 years) was significantly greater than during ages <17 (aHR = 1.79, 95%CI = 1.69–1.90, p < 0.001) and ages >24 (aHR = 1.11, 95%CI = 1.03–1.20, p = 0.005). In contrast, liver graft loss during ages 17–24 was no different than during ages <17 (aHR = 1.03, 95%CI = 0.92–1.16, p = 0.6) or ages >24 (aHR = 1.18, 95%CI = 0.98–1.42, p = 0.1). In simultaneous liver–kidney recipients, a trend towards increased kidney compared to liver graft loss was observed during ages 17–24 years. Late adolescence and early adulthood are less detrimental to pediatric liver grafts compared to kidney grafts, suggesting that sociobehavioral mechanisms alone may be insufficient to create the high–risk age window and that additional biologic mechanisms may also be required.

Abbreviations: aHR, adjusted hazard ratio; CAKUT, congenital anomalies of the kidney and urinary tract; FSGS, focal segmental glomerular sclerosis; HLA, human leukocyte antigen; HR, hazard ratio; KT, kidney transplant; LT, liver transplant; OPTN, organ procurement and transplantation network; PRA, panel reactive antibody; SLK, simultaneous liver kidney; SRTR, scientific registry of transplant recipients

Received 26 March 2014, revised 13 August 2014 and accepted for publication 15 August 2014

Introduction

Graft survival in pediatric kidney transplant (KT) recipients is strongly associated with recipient age. Recipients of a KT during their adolescent years have poorer long-term graft survival compared to recipients in other age groups (1–7). This disparity in graft survival is likely due to a significantly increased rate of graft loss during ages 17–24 (8,9), a high–risk age window through which all pediatric KT recipients must eventually pass regardless of the age at which transplantation is performed.

The exact etiology of increased graft loss during the high–risk age window is unknown. Potential sociobehavioral explanations include poor adherence to immunosuppression (10–16), loss of insurance coverage (17–19) and transitions from pediatric to adult care (14,20–25) during the patients’ teens to early twenties. Possible biologic mechanisms that may be specific to kidney grafts, such as hyperfiltration injury (26) during this period of increased growth or enhanced susceptibility to immunosuppression withdrawal, may also be involved or interact with the proposed sociobehavioral mechanisms. An examination of the extent to which the high–risk age window is equally detrimental to pediatric recipients of other transplants may shed light on which mechanisms are primarily at work in creating the high–risk age window in pediatric KT recipients.

If the mechanisms behind the high–risk age window of KT recipients are primarily nonbiologic and not specific to the kidney, one would expect a similar high–risk age window for liver transplant (LT) recipients given the likely similar difficulties with adherence, insurance and care transitions. In addition, one would expect liver and kidney grafts in pediatric simultaneous liver–kidney (SLK) recipients to be similarly subject to graft loss during the high–risk age window. On the other hand, however, differential kidney
Van Arendonk et al

and liver graft loss (especially within the same patient) would instead suggest that biologic in addition to socio-behavioral mechanisms must be involved. To better understand the mechanisms behind the high-risk age window after pediatric KT, the objective of this study was to compare graft loss of pediatric KT, LT and SLK transplant recipients during the high-risk age window of late adolescence and early adulthood.

Materials and Methods

Study population

This study utilized data from the Scientific Registry of Transplant Recipients (SRTR), a national registry of all solid organ transplants. The SRTR includes data on all donors, wait-listed candidates and transplant recipients in the United States, submitted by the members of the Organ Procurement and Transplantation Network (OPTN) and has been described elsewhere (27). The Health Resources and Services Administration, United States Department of Health and Human Services, provides oversight to the activities of the OPTN and SRTR contractors.

All pediatric (recipient age less than 18 years old at time of transplantation) kidney-only, liver-only and SLK recipients between October 1987 and through February 2012 were identified in the SRTR. Based on clinical knowledge and precedent set by the SRTR program-specific regression models (available at www.srtr.org), etiology of renal disease was categorized as either focal segmental glomerular sclerosis (FSGS), other glomerular diseases, congenital anomalies of the kidney and urinary tract (CAKUT) or other/missing diagnosis. Etiology of liver disease was categorized as either biliary atresia, metabolic disease, acute hepatic necrosis, malignancy or other/missing diagnosis.

Outcome ascertainment

All-cause graft survival was defined as the time between transplantation and either graft loss (marked by either retransplantation or additionally for KT recipients, a return to dialysis) or death, censoring for administrative end of study. All-cause graft survival was examined except where specified. In a sensitivity analysis, death-censored graft survival, defined as the time between transplantation and either graft loss (marked by retransplantation or a return to dialysis) or last date of follow-up with a functioning graft, with censoring for death and administrative end of study, was also examined. Death ascertainment was supplemented by linkage to the Social Security Death Master File; death and graft loss ascertainment were also supplemented by linkage to data from the Centers for Medicare and Medicaid Services.

Hazard plots and models

Survival analyses were conditioned on a minimum graft survival of 6 months to exclude the increased risk of graft loss in the immediate postoperative period. A sensitivity analysis without this 6 month conditioning was also performed. Graft failure rates were analyzed within various time intervals; specifically, seven-year graft failure rates were calculated to determine the likelihood of graft survival to age 24 given a functioning graft at age 17.

As previously reported (9), the risk of graft loss across age (in other words, the graft failure rate at a recipient’s current age) was graphically explored by plotting hazard functions against current recipient age (rather than the conventional posttransplant follow-up time). Age 0 (rather than date of transplantation) served as the time origin, with late entries into the risk set at each age of transplantation. The hazard function then provided the current graft failure rate at a given age conditional on graft survival up to that age. Stratified analyses were performed across donor type and age at transplantation to explore the possibility that differences in kidney and liver graft loss across age could be due to differences in donor type and timing of transplantation.

A piecewise-constant hazard rate model was used to quantify the hazard of graft loss across posttransplant age. This model is an exponential hazard model that assumes a constant hazard within predefined time segments and then estimates variation in hazard between time segments (28). Time segments were chosen as previously described (9). Given that the time axis in the analysis was current recipient age, the time segments therefore consisted of periods of age (rather than follow-up time), thus enabling a closer examination of the high-risk age window of ages 17–24 in comparison to the ages before and after this window.

A multivariable parameterization of the piecewise-constant hazard rate model was used to compare hazard between posttransplant age categories while adjusting for potential recipient (sex, race, insurance, diagnosis, previous transplant history), donor (living vs. deceased, age, and race) and center-level (pediatric transplant volume) confounders, as well as the year of transplantation. Dialysis history, peak panel reactive antibody (PRA) and HLA mismatch were additionally included in KT models. An unadjusted model was used to compare hazard in the SLK recipient group given the small sample size. All tests were two sided with statistical significance set at \( \alpha = 0.05 \). Analyses were performed using STATA 12.1/SE (College Station, TX).

Results

Study population

A total of 17,446 KT recipients, 12,161 LT recipients and 224 SLK recipients underwent transplantation during the study period (Table 1). The mean age at transplantation was older for KT recipients (11.6 years) compared to LT (5.4 years) and SLK (9.6 years) recipients. The most common known etiologies of disease were CAKUT for KT recipients and biliary atresia for LT recipients. Nearly half of the KT recipients received a living donor transplant (49.3%), while the proportion of LT recipients receiving a living donor transplant was only 11.6%. HLA mismatch was greater in LT and SLK recipients (80.2% and 87.2% having 4–6 mismatches, respectively) compared to KT recipients (55.6% having three or fewer mismatches).

Graft loss in kidney versus liver recipients

Graft loss among pediatric KT recipients (Figure 1A) was markedly elevated during late adolescence and early adulthood. In fact, in patients with a functioning graft at age 17, 43.3% were expected to lose the graft by age 24. Graft loss among pediatric LT recipients (Figure 1B) was less pronounced during late adolescence and early adulthood. In patients with a functioning graft at age 17, only 15.9% were expected to lose the graft by age 24.

After adjusting for recipient, donor and transplant characteristics, the hazard of graft loss in KT recipients during ages 17–24 was significantly greater than that during ages 0–17 (adjusted hazard ratio [aHR]: 1.79, 95% CI: 1.69–1.89;
### Table 1: Recipient, donor, transplant and center characteristics for pediatric (<18 years old) kidney, liver and simultaneous liver–kidney (SLK) transplants performed between 1987–2012

<table>
<thead>
<tr>
<th>Recipient</th>
<th>Kidney (n = 17,446)</th>
<th>Liver (n = 12,161)</th>
<th>SLK (n = 224)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (years) (SD)</td>
<td>11.6 (5.1)</td>
<td>5.4 (5.6)</td>
<td>9.6 (5.3)</td>
</tr>
<tr>
<td>Female Sex</td>
<td>40.8%</td>
<td>52.2%</td>
<td>52.7%</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>57.7%</td>
<td>57.7%</td>
<td>63.8%</td>
</tr>
<tr>
<td>African American</td>
<td>18.6%</td>
<td>17.9%</td>
<td>9.8%</td>
</tr>
<tr>
<td>Other</td>
<td>23.7%</td>
<td>24.3%</td>
<td>26.4%</td>
</tr>
<tr>
<td>Public insurance</td>
<td>64.1%</td>
<td>56.1%</td>
<td>54.3%</td>
</tr>
<tr>
<td>Etiology of disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FSGS</td>
<td>10.4%</td>
<td>1.3%</td>
<td></td>
</tr>
<tr>
<td>Other glomerular diseases</td>
<td>14.3%</td>
<td>3.1%</td>
<td></td>
</tr>
<tr>
<td>CAKUT</td>
<td>34.9%</td>
<td>25.9%</td>
<td></td>
</tr>
<tr>
<td>Other/missing</td>
<td>40.4%</td>
<td>27.9%</td>
<td>45.5%</td>
</tr>
<tr>
<td>Biliary atresia</td>
<td>42.9%</td>
<td>4.0%</td>
<td></td>
</tr>
<tr>
<td>Metabolic disease</td>
<td>11.9%</td>
<td>45.5%</td>
<td></td>
</tr>
<tr>
<td>Acute hepatic necrosis</td>
<td>12.6%</td>
<td>2.7%</td>
<td></td>
</tr>
<tr>
<td>Malignancy</td>
<td>4.7%</td>
<td>2.2%</td>
<td></td>
</tr>
<tr>
<td>Previous transplant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kidney</td>
<td>11.4%</td>
<td>0.2%</td>
<td>15.6%</td>
</tr>
<tr>
<td>Liver</td>
<td>0.4%</td>
<td>14.5%</td>
<td>9.5%</td>
</tr>
<tr>
<td>Simultaneous kidney liver</td>
<td>0.1%</td>
<td>0.1%</td>
<td>2.7%</td>
</tr>
<tr>
<td>Donor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean Age (years) (SD)</td>
<td>29.8 (12.7)</td>
<td>14.6 (14.7)</td>
<td>14.5 (12.4)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>68.5%</td>
<td>66.5%</td>
<td>66.5%</td>
</tr>
<tr>
<td>African American</td>
<td>12.7%</td>
<td>15.8%</td>
<td>16.1%</td>
</tr>
<tr>
<td>Other</td>
<td>18.8%</td>
<td>17.7%</td>
<td>17.4%</td>
</tr>
<tr>
<td>Living donor</td>
<td>48.7%</td>
<td>11.6%</td>
<td>0.0%</td>
</tr>
<tr>
<td>Transplant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA mismatch</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>4.2%</td>
<td>0.5%</td>
<td>0.0%</td>
</tr>
<tr>
<td>1-3</td>
<td>51.4%</td>
<td>19.3%</td>
<td>12.8%</td>
</tr>
<tr>
<td>4-6</td>
<td>44.4%</td>
<td>80.2%</td>
<td>87.2%</td>
</tr>
</tbody>
</table>

SD, standard deviation; FSGS, focal segmental glomerulosclerosis; CAKUT, congenital anomalies of the kidneys and urinary tract; HLA, human leukocyte antigen.

### Figure 1: Hazard of all-cause graft loss across current recipient age (with 95% confidence interval) among pediatric (A) kidney transplant recipients and (B) liver transplant recipients.

*American Journal of Transplantation 2015; 15: 445–452*
p < 0.001) and ages >24 (aHR 1.11, 95% CI: 1.03–1.20; p = 0.005). However, the hazard of graft loss in LT recipients during ages 17–24 was not significantly different compared to ages 0–17 (aHR 1.03, 95% CI: 0.92–1.16; p = 0.6) or ages >24 (aHR 1.18, 95% CI: 0.98–1.42; p = 0.1).

Similar findings were seen when death-censored graft survival was instead examined (Figure 2). Likewise, inferences were unchanged when examining all posttransplant follow-up time (i.e. without conditioning on a minimum graft survival of 6 months) (Figure 3). Finally, findings were consistent across donor type and recipient age at transplantation (Figure 4).

**Graft loss in simultaneous liver–kidney recipients**

For graft loss among SLK recipients, kidney graft loss during ages 17–24 appeared to be accentuated compared to liver graft loss. In patients with a functioning kidney at age 17, 19.1% were expected to lose the kidney graft by age 24, and in patients with a functioning liver at age 17, 10.5% were expected to lose the liver graft by age 24. The hazard of kidney graft loss for ages 17–24 appeared to be greater (although not statistically so) compared to ages 0–17 (hazard ratio [HR] 1.47, 95% CI: 0.65–3.32; p = 0.4) and was similar to ages >24 (HR 0.82, 95% CI: 0.26–2.58; p = 0.7). The hazard of liver graft loss for ages 17–24 was similar to both ages 0–17 (HR 0.98, 95% CI: 0.40–2.36; p = 0.9) and ages >24 (HR 0.86, 95% CI: 0.23–3.24; p = 0.8).

**Discussion**

In this national study of nearly 30,000 pediatric KT, LT and SLK recipients, we found a significant difference in the rate at which kidney and liver grafts are lost during the high–risk age window of late adolescence and early adulthood (8,9). Graft loss sharply peaks during this time period among KT recipients; however there is little change in the rate of graft loss across recipient age among LT recipients. Importantly, this finding was consistent in sensitivity analyses examining both death-censored graft survival (to focus specifically on graft failure given the suspected mechanism of nonadherence) and all posttransplant follow-up time (to avoid potential selection bias in examining only those with graft survival of at least 6 months). Among pediatric SLK recipients, a trend towards higher rates of kidney graft loss, compared to liver graft loss, was also observed during the high–risk age window, although the small sample size limited definitive conclusions.

The increased risk of graft loss during late adolescence and early adulthood among pediatric KT recipients has been attributed to lack of adherence to immunosuppression (10–16), alterations in health insurance coverage (17–19) and transitions from pediatric to adult care (14,20–24). These issues are not unique to pediatric KT recipients, however. Pediatric LT recipients, as expected, have been found to have similar difficulties with immunosuppression adherence, insurance, and care transitions (29–32). While nonadherence between kidney and liver recipients may not be identical given the different immunosuppression regimens that are required, one would still expect to find at least some level of a high–risk age window among pediatric LT recipients, even if attenuated. However, no statistically appreciable increased risk of graft loss during these ages was identified among LT recipients.

The absence of a high–risk age window in pediatric LT recipients may be related to the biologic differences between kidney and liver grafts. The period of increased growth during adolescence could lead to hyperfiltration injury within kidney grafts, and thereby subsequent increased rates of graft loss, similar to the hyperfiltration injury thought to occur when kidneys from small donors are transplanted into large recipients (26). On the other hand...

![Figure 2](image_url): Hazard of death-censored graft loss across current recipient age (with 95% confidence interval) among pediatric (A) kidney transplant recipients and (B) liver transplant recipients.
Figure 3: Hazard of all-cause graft loss (without conditioning on a minimum graft survival of 6 months) across current recipient age (with 95% confidence interval) among pediatric (A) kidney transplant recipients and (B) liver transplant recipients.

Figure 4: Hazard of all-cause graft loss across current recipient age, stratified by donor type and age at transplantation, among pediatric kidney (A and C) and liver (B and D) transplant recipients.
hand, liver grafts may be able to sustain this period of growth without injury given the concurrent growth of liver grafts within pediatric recipients as they grow (33,34). Liver grafts have been shown to develop significant histologic changes over time though, including signs of chronic hepatitis and fibrosis (35,36). The exact clinical relevance of these histologic changes is not entirely clear, however; nor is it known if the incidence of these changes peaks within any particular age group, or rather if the changes just accumulate with a longer duration of time since transplantation.

The difference in kidney and liver graft loss during the high-risk age window may also be related to a reduced susceptibility to immunosuppression withdrawal (or sporadic usage) among liver grafts. Indeed, recent success has been found with early immunosuppression withdrawal among pediatric LT recipients (37,38). In this way, our study could indirectly lend additional support to the promise of achieving tolerance within pediatric LT recipients. Finally, and perhaps most likely, the explanation for the difference in kidney and liver graft loss during the high-risk age window may be an interaction between any of the aforementioned potential mechanisms.

Pediatric KT and LT recipients have two other notable differences that may contribute to the difference in kidney and liver graft loss seen during the high-risk age window. Specifically, pediatric LT recipients more frequently receive deceased donor organs and are generally transplanted at younger ages compared to pediatric KT recipients, highlighting the importance of our sensitivity analyses showing that inferences were consistent across donor type and recipient age at transplantation. In examining graft loss risk stratified by donor type, living donor organs among pediatric LT recipients, in contrast to among pediatric KT recipients, appeared to have little benefit in terms of graft survival compared to deceased donor organs, consistent with other studies showing similar graft survival between deceased donor and living donor LT in pediatric recipients (39,40). This may reflect differential sensitivity to cold ischemia, importance of HLA matching or importance of technical issues related to graft types or other differences between LT and KT. Also, stratification by age at transplantation showed that despite transplantation at different ages, pediatric KT grafts are most at risk during late adolescence and early adulthood, in contrast to the relatively stable risk seen among pediatric LT grafts. This finding further supports the hypothesis that kidney grafts, regardless of the time since transplantation, may be especially vulnerable to the increasing physiologic demands placed on the graft with the significant growth and maturation that occurs during late adolescence and early adulthood, a vulnerability that may be absent or diminished among liver grafts.

Pediatric SLK recipients provide a unique study population to compare the differential kidney and liver graft loss during the high-risk age window. SLK recipients essentially provide the desired counterfactual comparison between kidney and liver grafts; in other words, SLK recipients enable comparison of two organs within an otherwise identical patient in an otherwise identical behavioral, environmental and social setting (in fact, the same patient in the same setting). If differential kidney and liver graft loss within the same patient were to be observed, it would provide strong evidence that biologic mechanisms in addition to social mechanisms are likely involved in creating the high-risk age window seen among pediatric KT recipients. Although the sample size for SLK recipients in this study was quite small, a trend towards increased kidney graft loss compared to liver graft loss during the high-risk age window did appear.

This study is limited by the small sample size of the SLK recipient group and the resulting difficulty in providing a robust statistical comparison between kidney and liver graft loss in these recipients. However, the large sample sizes for the KT and LT recipient groups still provide ample and robust evidence of a clear difference in pediatric kidney and liver graft loss during the high-risk age window. In addition, the study is limited by the variables available in the SRTR. Ideally, graft loss during the high-risk age window could be compared both across organ type and across varying degrees of immunosuppression adherence and insurance coverage. The SRTR unfortunately lacks granularity with respect to both adherence and insurance status and their changes over time, as well as other important factors such as the timing of the care transition process, the specific immunosuppression regimens used and recipient cognitive function.

In conclusion, our comparison of graft loss in pediatric KT, LT and SLK recipients found that the high-risk age window of late adolescence and early adulthood is significantly less detrimental in terms of liver graft loss compared to kidney graft loss. This finding suggests that sociobehavioral mechanisms alone may be insufficient to create a high-risk age window after pediatric transplantation. Instead an interaction between the previously suggested sociobehavioral mechanisms and other biologic mechanisms, such as differential susceptibility to immunosuppression withdrawal, may be responsible for the exceptionally high rate of graft loss seen among pediatric KT recipients during late adolescence and early adulthood.

Acknowledgments

This work was supported in part by grant number K24DK101828 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This research was presented in preliminary form as an oral abstract at the 2013 American Society of Transplant Surgeons State of the Art Winter Symposium and the 2013 American Transplant Congress. The Minneapolis Medical Research Foundation as the contractor for the SRTR has supplied the data reported here. The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an endorsement by the SRTR, its contractors, or the National Institutes of Health.
Disclosure

The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

References

Van Arendonk et al